Experian (LSE:EXPN)’s takeover of Illion could pave the way for further merger and acquisition activity and should add value in as few as three years, analysts have said.
The credit rating specialist announced the AU$820 million (£427.2 million) purchase of the Australian and New Zealand-based consumer and commercial credit bureau on Thursday.
Investment trusts are just at the beginning of what could be a 25-month recovery cycle, according to a research piece from Peel Hunt, which has sifted its selections into good, bad and ugly.
“These are still some of the wildest discounts that we have seen in a long time” it says, but with an average recovery period is 25 months there is a long way to go and investors have plenty of opportunity to participate.
Shell Plc's (LSE:SHEL, NYSE:SHEL) trading statement on Friday has been described as “overall a positive update”, as analysts at Jefferies repeated a ‘buy’ recommendation for the London-listed oil major.
Earlier today, Shell gave investors a first quarter update and forecast its integrated gas production to range between 960 to 1,000 thousand barrels of oil equivalent per day (kboe/d).
AstraZeneca PLC (LSE:AZN)'s positive data from Imfinzi’s Phase III ADRIATIC trial follows the raft of positive readouts and approvals across a range of cancer types, notes Shore Capital.
Already these have stimulated a strong uptick in sales momentum for its burgeoning IO (immunotherapy) franchise during 2023 ($4.24bn, +55% CER).
Union Jack commencing trading on the US OTCQB Venture Market is an interesting move suggests house broker Shore Capital.
While AIM will remain the primary listing, the US listing increases liquidity, widens the pool of potential investors and raises its domestic profile in the US.